← brief for 2026-10-07 · Slowing decline

A meta-analysis on the efficacy and safety of obinuzumab for membranous nephropathy.

Article A Peer reviewed Meta-analysis or large trial

Key takeaways

This meta-analysis looked at studies of a drug called obinutuzumab. It is used to treat a kidney condition called membranous nephropathy. The analysis found that this drug may be more effective than an older drug called rituximab. It helps reduce protein in the urine, which is a sign of kidney damage.

Who did this work

Yu LX · Qian CL · Qian JR · Qi-Zhang · Yang XL · Liu QF

Source

Article · PubMed, Reducing protein and albumin in urine · 2026 Mar 27
https://pubmed.ncbi.nlm.nih.gov/42840985/